| Manufacturer |
Eli Lilly and Company |
Eli Lilly and Company |
| Pricing |
Manufacturer pricing and savings options:
- Retail Pricing: Standard cash prices can exceed $1,000 per month without insurance or discounts.
- Commercial Insurance: Eligible patients may qualify for manufacturer savings that substantially reduce copayments.
- Out-of-Pocket Costs: Depend on insurance coverage, dosage, pharmacy pricing, and savings-program eligibility.
Manufacturer savings offers and eligibility requirements may change.
|
Manufacturer self-pay options:
- Starting Price: $149/month for the 0.8 mg starting dose through eligible LillyDirect self-pay options.
- Intermediate Doses: $149/month for 2.5 mg and $199/month for 5.5 mg under promotional pricing through December 31, 2026.
- Higher Doses: Starting at $299/month for 9 mg, 14.5 mg, and 17.2 mg, subject to qualifying program and refill requirements.
Regular prices and eligibility conditions vary by dose.
|
| Insurance Coverage |
- Commercial Insurance: Many plans cover Mounjaro for eligible patients with type 2 diabetes.
- Medicare Part D: Coverage may be available for qualifying beneficiaries with diabetes.
- Weight Loss Alone: Coverage is generally restricted because Mounjaro is not specifically approved for chronic weight management.
|
- Commercial Insurance: Some plans cover Foundayo for eligible patients with obesity or qualifying overweight.
- Prior Authorization: Coverage may require documentation of BMI, weight-related conditions, and medical necessity.
- Manufacturer Savings: Eligible commercially insured patients with coverage may qualify for reduced copayments.
|
| Main Purpose |
Improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes. |
Long-term weight loss and weight maintenance in adults with obesity or qualifying overweight. |
| Secondary Purposes |
- Cardiovascular Protection: Reduce major cardiovascular events in adults with type 2 diabetes who are at high risk.
- Weight Reduction: May produce substantial weight loss during diabetes treatment.
|
- Appetite Regulation: Reduce hunger and calorie intake to support sustained weight management.
- Metabolic Health: May improve certain weight-related metabolic measures, including blood sugar regulation.
|
| Active Ingredient |
Tirzepatide, a dual GIP and GLP-1 receptor agonist. |
Orforglipron, an oral small-molecule GLP-1 receptor agonist. |
| Benefits |
- Blood Sugar Control: Significantly reduces HbA1c and blood glucose in patients with type 2 diabetes.
- Weight Reduction: Can produce substantial weight loss during diabetes treatment.
- Cardiovascular Protection: Reduces major cardiovascular events in qualifying adults with type 2 diabetes.
- Convenience: Requires only one injection per week.
|
- Weight Loss: Produces clinically meaningful weight reduction in eligible adults.
- Appetite Regulation: Reduces hunger and promotes feelings of fullness.
- Oral Administration: Offers weight-management treatment without injections.
- Convenience: Can be taken with or without food and without special water-intake restrictions.
|
| Potential Health Risks |
- Pancreatitis: Potential acute pancreatic inflammation.
- Gallbladder Problems: Including gallstones and gallbladder inflammation.
- Kidney Injury: Possible dehydration-related acute kidney injury.
- Low Blood Sugar: Increased risk when combined with insulin or insulin secretagogues.
- Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rats.
|
- Pancreatitis: Potential acute pancreatic inflammation.
- Gallbladder Problems: Including gallstones and gallbladder inflammation.
- Kidney Injury: Possible dehydration-related acute kidney injury.
- Drug Interactions: Certain CYP3A4 inhibitors, inducers, and other medications may require precautions or dosage adjustments.
- Thyroid Warning: Boxed warning concerning the potential risk of thyroid C-cell tumors associated with GLP-1 receptor activity.
|
| Weight Loss Potential |
Can produce substantial weight loss in adults with type 2 diabetes. In the SURPASS-2 diabetes trial, tirzepatide produced average weight reductions of approximately 7.6–11.2 kg after 40 weeks, depending on dosage. These are Mounjaro-relevant diabetes-treatment results and should not be confused with the larger weight-loss percentages reported in trials of Zepbound. |
Approximately 7.4%–11.1% average body-weight reduction after 72 weeks in a major clinical trial involving adults without diabetes, depending on dosage. Foundayo is FDA-approved specifically for chronic weight management. Its results cannot be directly compared with Mounjaro’s diabetes trials because study populations, durations, and treatment objectives differ. |
| Administration |
- Injection: Subcutaneous injection once weekly.
- Injection Sites: Abdomen, thigh, or upper arm.
- Available Forms: Single-dose injection pens and approved multidose KwikPen presentations.
|
- Oral Tablet: Taken once daily.
- Food Requirements: Can be taken with or without food.
- Water Requirements: No special water-intake restrictions.
|
| Dosing Considerations |
- Starting Dose: Typically 2.5 mg once weekly.
- Dose Escalation: Increase to 5 mg after four weeks, with further increases based on blood sugar response and tolerability.
- Maximum Dose: 15 mg weekly for adults and 10 mg weekly for children aged 10 years and older.
|
- Starting Dose: 0.8 mg once daily.
- Dose Escalation: Gradual increases to 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg, with at least 30 days between increases.
- Maximum Dose: 17.2 mg daily, subject to tolerability and drug-interaction restrictions.
|
| Who May Benefit Most? |
Adults and children aged 10 years and older with type 2 diabetes who need improved blood sugar control, particularly adults at high cardiovascular risk who may also benefit from Mounjaro’s cardiovascular indication. |
Adults with obesity or qualifying overweight who need FDA-approved chronic weight management and prefer an oral medication without injections or food-related administration restrictions. |
| How Fast Does It Work? |
- Blood Sugar: Improvements may begin within the first several weeks.
- HbA1c: Reductions are generally assessed over approximately 3 months.
- Weight Loss: Typically develops gradually over several months.
|
- Appetite: Changes may begin within the first several weeks.
- Initial Weight Loss: May become noticeable within the first month or two.
- Substantial Weight Loss: Generally develops over several months, with major trials assessing outcomes at 72 weeks.
|
| Potential Side Effects |
- Digestive: Nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion.
- Other Effects: Decreased appetite and possible injection-site reactions.
- Timing: Gastrointestinal symptoms frequently occur when starting treatment or increasing dosage.
|
- Digestive: Nausea, constipation, diarrhea, vomiting, abdominal pain, and indigestion.
- Other Effects: Headache, fatigue, bloating, acid reflux, and possible hair loss.
- Timing: Gastrointestinal symptoms frequently occur during initial treatment and dose escalation.
|